Analysts Upgrade/Downgrade Activity of Merck & Co., Inc. (NYSE:MRK)


Merck & Co., Inc. (NYSE:MRK) belonging to the Medical sector has declined -1.93% and closed its last trading session at $59.92.

The consensus recommendation, according to Zacks Investment research, is 2. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.86 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.86 and 2.08 respectively.

The Company got Downgrade by Jefferies on 19-Dec-16 from Hold to Underperform.

Insider Trades for Merck & Co., Inc. show that the latest trade was made on 9 Nov 2016 where Frazier (Kenneth C), the Chief Executive Officer completed a transaction type “Buy” in which 133920 shares were traded at a price of $23.45.

6 Insider Sales transactions were made totaling 389423 shares traded.

Merck & Co., Inc. (NYSE:MRK) has the market capitalization of $165.68 Billion. The company rocked its 52-Week High of $65.46 on Nov 10, 2016 and touched its 52-Week Low of $47.97 on Feb 8, 2016. The stock has Return on Assets (ROA) of 5.6 percent. Return on Equity (ROE) stands at 12.5% and Return on Investment (ROI) of 6.4 percent.

The stock is currently showing YTD performance of 1.78 Percent. The company has Beta Value of 0.78 and ATR value of 1. The Weekly and Monthly Volatility stands at 1.67% and 1.56%.

Company profile:

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.